Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Dillione Janet	2. Issuer Name and Ticker or Trading Symbol CorMedix Inc. [ CRMD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O CORMEDIX INC., 300 CONNELL DRIVE, SUITE 4200	3. Date of Earliest Transaction (MM/DD/YYYY) 11/16/2020
(Street) BERKELEY HEIGHTS, NJ 07922 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock								53473.0000	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Phantom Stock	$0.0000	11/16/2020		A		3583.0000		⁽¹⁾	⁽¹⁾	Common Stock	3583.0000	$0.0000	3583.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	4770.0000		4770.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	5253.0000		5253.0000	D
Stock Option (Right to Buy Common Stock)	$5.6300							⁽²⁾	2/25/2030	Common Stock	15000.0000		15000.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	1706.0000		1706.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	2099.0000		2099.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	945.0000		945.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	1126.0000		1126.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	843.0000		843.0000	D
Stock Option (Right to Buy Common Stock)	$8.3000							⁽³⁾	1/10/2029	Common Stock	15000.0000		15000.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	1328.0000		1328.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	2728.0000		2728.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	7500.0000		7500.0000	D
Stock Option (Right to Buy Common Stock)	$2.8500							⁽⁴⁾	2/16/2028	Common Stock	8000.0000		8000.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	2679.0000		2679.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	3125.0000		3125.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	4167.0000		4167.0000	D
Stock Option (Right to Buy Common Stock)	$11.2000							⁽⁵⁾	2/21/2027	Common Stock	8000.0000		8000.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	695.0000		695.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	829.0000		829.0000	D
Stock Option (Right to Buy Common Stock)	$15.1500							⁽⁶⁾	8/11/2025	Common Stock	10000.0000		10000.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	283.0000		283.0000	D
Stock Option (Right to Buy Common Stock)	$9.5500							⁽⁷⁾	2/21/2026	Common Stock	19000.0000		19000.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	767.0000		767.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	554.0000		554.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	867.0000		867.0000	D
Phantom Stock	$0.0000							⁽¹⁾	⁽¹⁾	Common Stock	3062.0000		3062.0000	D

Explanation of Responses:
(1)	Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director.
(2)	These options were granted on 02/25/2020. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board.
(3)	These options were granted on 01/10/2019. These options are fully vested.
(4)	These options were granted on 02/16/2018. These options are fully vested.
(5)	These options were granted on 02/21/2017. These options are fully vested.
(6)	These options were granted on 08/12/2015. These options are fully vested.
(7)	These options were granted on 02/21/2016. These options are fully vested.

Remarks:
The Issuer effected a 1-for-5 reverse stock split of its common stock on March 26, 2019. All share and per share exercise price amounts shown in this Form 4 have been adjusted to reflect the reverse stock split.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Dillione Janet C/O CORMEDIX INC. 300 CONNELL DRIVE, SUITE 4200 BERKELEY HEIGHTS, NJ 07922	X